TIDMDEST
RNS Number : 3876B
Destiny Pharma PLC
10 June 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Data to be presented from the successful Phase 2b clinical study
of XF-73 nasal gel at the prestigious 2021 ECCMID congress
-- XF-73 met its primary end point with >99% nasal S. aureus reduction within 24 hours
-- Excellent clinical safety profile for XF-73 dosed in patients scheduled for cardiac surgery
-- Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract
Brighton, United Kingdom - 10(th) June 2021 - Destiny Pharma plc
(AIM: DEST), a clinical stage innovative biotechnology company
focused on the development of novel medicines to prevent
life-threatening infections, today announces that an abstract
providing analysis and discussion of the late-breaking data arising
from the recently completed Phase 2b clinical study of XF-73 nasal
gel has been accepted for presentation at Europe's premier
antimicrobials congress, the 31st European Congress of Clinical
Microbiology & Infectious Diseases (ECCMID), to be held 9 - 12
July, 2021.
Presentation Title : Repeated doses of exeporfinium chloride
(XF-73) nasal gel over 24 hours significantly reduced the burden of
Staphylococcus aureus nasal carriage in at-risk surgical patients:
preliminary results from a Phase 2 study. The presentation will
update the audience on the following highlights:
-- Met primary endpoint: XF-73 reduced the mean nasal burden of
S. aureus in patients undergoing open heart surgery by 2.5 log
(CFU/ml) in the 24 hours immediately before surgery a highly
statistically significant result, (p<0.0001). This equates to a
99.5% reduction in S. aureus bacterial nasal carriage, which is a
very effective reduction by accepted clinical measures.
-- XF-73 showed 2.1 log, (>99%), greater reduction than
placebo in the same patient population and this difference in
reduction of nasal burden of S. aureus was highly statistically
significant (p<0.0001). The effect was maintained during
surgery, considered the period when the risk for infections is the
highest.
-- These positive results were achieved with just three doses of
0.2% (w/w) XF-73 nasal gel in the 24 hours before incision and the
start of surgery.
-- There were no XF-73 nasal gel treatment related adverse events.
Presenting Author: Julie Mangino MD, FSHEA, FIDSA, Professor
Emeritus, Department of Internal Medicine, Division of Infectious
Diseases, The Ohio State University College of Medicine, US
Abstract # : 04905
Session : LB: Late breaking clinical trial data
Session code : S182
ECCMID ( https://www.eccmid.org/ ) is the world's premier
Clinical Microbiology & Infectious Diseases event, bringing
together experts from many fields to present their latest findings,
and developments and share their expertise.
XF-73 is the lead drug candidate from Destiny Pharma's XF
platform, initially being developed for the prevention of
post-surgical staphylococcal infections, such as
methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the
hospital setting. XF-73 has been awarded both Qualified Infectious
Disease Product ( QIDP) and Fast Track status by the US FDA.
If you would like to meet with Destiny Pharma, please email us
on conferences@destinypharma.com
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com
finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330
About Destiny Pharma plc
Destiny Pharma is a UK based, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that can prevent life-threatening infections. Its pipeline has
novel microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence, which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections, and has earlier grant funded XF
research projects.
For further information on the company, please visit https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPUCCQUPGGAB
(END) Dow Jones Newswires
June 10, 2021 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024